Antalia Pharma was established in early 2015, in the middle of the most severe financial crisis that hit Greece for a generation. In spite of the disruptive political and business environment, a team of professional people who believed in doing things differently set out with the objective of creating a collaborative platform that could generate long-standing value for its partners. Soon after, the first office of Antalia opened in Athens followed by affiliates and associate offices in various parts of the world.

Since its inception, Antalia Pharma has put in place an open and interactive organization that encompasses its customers and suppliers, with the aim to serve its fast-growing OTC market. It develops strategic partnerships with major distributors in several territories for faster and risk-assessed market penetration of its brands.

• In the first year of its creation, it managed to develop and establish its first 2 brands, Arena and Tempufen.
• One year later, Antalia Pharma set up its first two, fully operational commercial subsidiaries in Turkey and Canada and plans to establish more in the near future.
• On its 4^rd anniversary, Antalia Pharma in-licensed, developed, manufactured and introduced into European markets the first world-patented and clinically backed nutritional supplement for Cardio patients and other heart and cardiovascular diseases. Additionally, its pipeline includes the first well-documented food supplement for Down Syndrome patients, produced through a unique and pioneering manufacturing process.

Our Practice & Core Values

Our Team